BAP1 is altered in 2.57% of malignant solid tumor patients with BAP1 Loss present in 0.26% of all malignant solid tumor patients [4].

BAP1 Loss is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BAP1 Loss and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

BAP1 is altered in 6.13% of melanoma patients with BAP1 Loss present in 0.09% of all melanoma patients [4].

BAP1 Loss is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain BAP1 Loss and melanoma as inclusion criteria, 3 are phase 2 (3 open) [5].

BAP1 is altered in 46.24% of malignant mesothelioma patients with BAP1 Loss present in 9.55% of all malignant mesothelioma patients [4].

BAP1 Loss is an inclusion criterion in 2 clinical trials for malignant mesothelioma, of which 1 is open and 1 is closed. Of the trials that contain BAP1 Loss and malignant mesothelioma as inclusion criteria, 2 are phase 2 (1 open) [5].

BAP1 is altered in 5.11% of urothelial carcinoma patients with BAP1 Loss present in 0.18% of all urothelial carcinoma patients [4].

BAP1 Loss is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BAP1 Loss and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BAP1 is altered in 49.41% of peritoneal mesothelioma patients with BAP1 Loss present in 18.75% of all peritoneal mesothelioma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and peritoneal mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 is altered in 44.88% of pleural mesothelioma patients with BAP1 Loss present in 8.54% of all pleural mesothelioma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 is altered in 3.98% of small cell lung carcinoma patients with BAP1 Loss present in 3.2% of all small cell lung carcinoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 is altered in 1.13% of mantle cell lymphoma patients with BAP1 Loss present in 0.58% of all mantle cell lymphoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BAP1 is altered in 0.77% of diffuse large B-cell lymphoma patients with BAP1 Loss present in 0.4% of all diffuse large B-cell lymphoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BAP1 is altered in 0.96% of malignant soft tissue neoplasm patients with BAP1 Loss present in 0.38% of all malignant soft tissue neoplasm patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for malignant soft tissue neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and malignant soft tissue neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 is altered in 0.29% of mature T-cell and NK-cell non-hodgkin lymphoma patients with BAP1 Loss present in 0.31% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BAP1 is altered in 0.56% of lymphoma patients with BAP1 Loss present in 0.26% of all lymphoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 is altered in 13.17% of renal cell carcinoma patients with BAP1 Loss present in 0.23% of all renal cell carcinoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BAP1 is altered in 0.7% of pancreatic adenocarcinoma patients with BAP1 Loss present in 0.16% of all pancreatic adenocarcinoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BAP1 is altered in 4.96% of bladder carcinoma patients with BAP1 Loss present in 0.13% of all bladder carcinoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BAP1 is altered in 2.53% of endometrial carcinoma patients with BAP1 Loss present in 0.05% of all endometrial carcinoma patients [4].

BAP1 Loss is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].